Premium
Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti‐TNF failure—getting closer to the truth. Authors' reply
Author(s) -
Biemans Vince B. C.,
Hoentjen Frank,
Pierik Marieke J.
Publication year - 2020
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/apt.16062
Subject(s) - vedolizumab , ustekinumab , medicine , crohn's disease , crohn disease , disease , gastroenterology , adalimumab